Publication details

CHARAKTERISTIKY PACIENTŮ S NSCLC A AKTIVAČNÍMI MUTACEMI EGFR LÉČENÝCH INHIBITORY TYROZINKINÁZY PO STANOVENÍ DIAGNÓZY - REÁLNÁ DATA Z ČESKÉ REPUBLIKY

Title in English Characteristics of patients with NSCLC and activating mutations EGFR treated with tyrosine kinase inhibitors: Real data from the Czech Republic
Authors

SKŘIČKOVÁ Jana CHLOUPKOVÁ Renata BORTLÍČEK Zbyněk HEJDUK Karel BRABEC Petr DUŠEK Ladislav PEŠEK M. KOLEK V. GRYGÁRKOVÁ I. KOUBKOVÁ L. ČERNOVSKÁ M. TOMÍŠKOVÁ Marcela ROUBEC J. HAVEL L. SALAJKA F. HRNČIAK M. ZEMANOVÁ M. ŠATÁNKOVÁ M. BENEJOVÁ A. SIXTOVÁ D. MEREL M. KREJČÍ J. OPÁLKA P. ČOUPKOVÁ H.

Year of publication 2017
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Description Three tyrosin kinase inhibitors – gefitinib, afatinib, erlotinib – were compared in 323 NSCLC patients. No significant differences were found in the outcomes of the treatments or other characteristics.

You are running an old browser version. We recommend updating your browser to its latest version.

More info